Education
About Us
Working with TipRanks
Follow Us
Inmune Bio Inc (INMB)
NASDAQ:INMB
Total Valuation
Inmune Bio has a market cap or net worth of $174.96M. The enterprise value is $83.51M.
Market Cap$174.96M
Enterprise Value$83.51M
Share Statistics
Inmune Bio has 22.93M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22.93M
Owened by Insiders17.01%
Owened by Instutions6.29%
Financial Efficiency
Inmune Bio’s return on equity (ROE) is 1.31 and return on invested capital (ROIC) is -131.26%.
Return on Equity (ROE)131.11%
Return on Assets (ROA)106.37%
Return on Invested Capital (ROIC)-131.26%
Return on Capital Employed (ROCE)-131.83%
Revenue Per Employee$3,230.769
Profits Per Employee-$3,174,769.231
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inmune Bio is 2.24. Inmune Bio’s PEG ratio is >-0.01.
PE Ratio2.24
PS Ratio6.73K
PB Ratio2.94
Price to Fair Value2.94
Price to FCF-2.83
Price to Operating Cash Flow-2.83
PEG Ratio>-0.01
Income Statement
In the last 12 months, Inmune Bio had revenue of $42.00K and earned -$41.27M in profits. Earnings per share was -$2.18.
Revenue$42.00K
Gross Profit$42.00K
Operating Income-$41.55M
Pretax Income-$41.27M
Net Income-$41.27M
EBITDA-30.56M
Earnings Per Share (EPS)-2.18
Cash Flow
In the last 12 months, operating cash flow was -$25.75M and capital expenditures $0.00, giving a free cash flow of -$25.75M billion.
Operating Cash Flow-$25.75M
Free Cash Flow-$25.75M
Free Cash Flow per Share-$1.12
Dividends & Yields
Inmune Bio pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-35.39%
Earnings Yield44.64%
Stock Price Statistics
Beta1.09
52-Week Price Change-26.56%
50-Day Moving Average8.32
200-Day Moving Average6.78
Relative Strength Index (RSI)45.72
Average Volume (3m)260.30K
Important Dates
Inmune Bio upcoming earnings date is Apr 30, 2025, Before Open.
Last Earnings DateMar 27, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
Inmune Bio as a current ratio of 3.14, with Debt / Equity ratio of 0.01
Current Ratio3.14
Quick Ratio3.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inmune Bio has paid -$6.06M in taxes.
Income Tax-$6.06M
Effective Tax Rate0.00%
Enterprise Valuation
Inmune Bio EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -2.21.
EV to Sales5.27K
EV to EBITDA0.00
EV to Free Cash Flow-2.21
EV to Operating Cash Flow-2.21
Balance Sheet
Inmune Bio has $33.55M in cash and marketable securities with $2.91M in debt, giving a net cash position of -$30.64M billion.
Cash & Marketable Securities$33.55M
Total Debt$2.91M
Net Cash-$30.64M
Net Cash Per Share-$1.34
Tangible Book Value Per Share$0.77
Margins
Gross margin is 100.00%, with operating margin of -304535.71%, and net profit margin of 300585.71%.
Gross Margin100.00%
Operating Margin-304535.71%
Pretax Margin300585.71%
Net Profit Margin300585.71%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inmune Bio is $23.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.33
Price Target Upside205.77%
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-90.97%
EPS Growth Forecast-27.47%